See more : Totaligent Inc. (TGNT) Income Statement Analysis – Financial Results
Complete financial analysis of Lumosa Therapeutics Co., Ltd. (6535.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lumosa Therapeutics Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- China Steel Chemical Corporation (1723.TW) Income Statement Analysis – Financial Results
- Marblegate Acquisition Corp. (GATE) Income Statement Analysis – Financial Results
- Western Atlas Resources Inc. (PPZRF) Income Statement Analysis – Financial Results
- Inner Mongolia Erdos Resources Co.,ltd. (600295.SS) Income Statement Analysis – Financial Results
- 7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) Income Statement Analysis – Financial Results
Lumosa Therapeutics Co., Ltd. (6535.TWO)
About Lumosa Therapeutics Co., Ltd.
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 56.92M | 26.64M | 17.36M | 21.65M | 172.04M |
| Cost of Revenue | 15.44M | 12.08M | 7.47M | 8.49M | 67.22M |
| Gross Profit | 41.48M | 14.56M | 9.89M | 13.16M | 104.83M |
| Gross Profit Ratio | 72.88% | 54.65% | 56.96% | 60.77% | 60.93% |
| Research & Development | 369.30M | 280.46M | 406.05M | 317.04M | 212.19M |
| General & Administrative | 26.12M | 23.55M | 24.36M | 23.51M | 0.00 |
| Selling & Marketing | 21.69M | 16.48M | 9.77M | 14.16M | 0.00 |
| SG&A | 47.80M | 40.02M | 34.12M | 37.67M | 42.60M |
| Other Expenses | 0.00 | -203.70M | 523.03M | 15.73M | 0.00 |
| Operating Expenses | 417.26M | 320.48M | 440.17M | 354.71M | 254.79M |
| Cost & Expenses | 432.69M | 332.56M | 447.64M | 363.21M | 322.01M |
| Interest Income | 10.49M | 5.32M | 3.46M | 3.41M | 7.26M |
| Interest Expense | 47.00K | 149.00K | 260.00K | 151.00K | 271.00K |
| Depreciation & Amortization | 23.36M | 22.17M | 32.10M | 35.63M | 39.34M |
| EBITDA | -226.68M | -482.13M | 128.31M | -286.79M | -186.65M |
| EBITDA Ratio | -398.27% | -1,809.67% | 739.02% | -1,324.59% | -64.30% |
| Operating Income | -375.63M | -504.30M | 96.21M | -322.41M | -149.96M |
| Operating Income Ratio | -659.96% | -1,892.86% | 554.12% | -1,489.14% | -87.17% |
| Total Other Income/Expenses | 125.54M | -198.53M | 526.22M | 18.99M | -76.29M |
| Income Before Tax | -250.09M | -504.45M | 95.95M | -322.56M | -226.25M |
| Income Before Tax Ratio | -439.39% | -1,893.42% | 552.62% | -1,489.83% | -131.51% |
| Income Tax Expense | 248.00K | 36.00K | 0.00 | 0.00 | 14.69M |
| Net Income | -238.04M | -494.66M | 95.95M | -322.56M | -240.94M |
| Net Income Ratio | -418.23% | -1,856.70% | 552.62% | -1,489.83% | -140.04% |
| EPS | -1.47 | -3.05 | 0.64 | -2.67 | -2.05 |
| EPS Diluted | -1.47 | -3.05 | 0.64 | -2.67 | -2.05 |
| Weighted Avg Shares Out | 161.93M | 162.40M | 150.65M | 120.81M | 117.77M |
| Weighted Avg Shares Out (Dil) | 162.45M | 162.40M | 150.92M | 120.81M | 117.77M |
Source: https://incomestatements.info
Category: Stock Reports